Adams Respiratory Therapeutics and Hollister-Stier Laboratories to co-promote ALLERx(TM) dose pack
Co-promotion plan announced
Chester, New Jersey – April 5th, 2004 – Adams Respiratory Therapeutics has formed an alliance with Hollister-Stier Laboratories LLC to promote Adams' ALLERxTM Dose Pack, a day/night treatment regimen for symptoms associated with allergic rhinitis, non-allergic rhinitis, vasomotor rhinitis and the common cold.
With the HollisterStier team calling on over 3,000 Allergists and Otolaryngologists nationally and Adams continuing to focus on Primary Care physicians, this alliance is designed to greatly heighten awareness of ALLERxTM Dose Pack as an important treatment option.
"We're excited to be working in concert with HollisterStier," remarked Mike Valentino, President and CEO of Adams Respiratory Therapeutics. "This co-promotion will expose additional physicians to the unique profile and benefits of ALLERxTM Dose Pack. HollisterStier's longstanding rapport with these important physician segments will be a key element in making this a successful venture."
"Having a product with the unique attributes of ALLERxTM Dose Pack will certainly strengthen our portfolio and create a real marketing opportunity for both parties," agreed Anthony D. Bonanzino, Ph.D., President & CEO of HollisterStier.
Located in Spokane, Washington, HollisterStier is a worldwide leader in the manufacture of allergenic extracts, targeted primarily at treating allergy and asthma. Their customer base includes over 3,000 Allergists/Immunologists and Otolaryngologists that specialize in allergic disease. HollisterStier enjoys a longstanding, close franchise with this group of specialists. In addition to its Allergy Business, HollisterStier is a nationally recognized contract manufacturer of sterile injectable vials, syringes and lyophilized products for the pharmaceutical and biopharmaceutical industries.
Headquartered in Chester, New Jersey, Adams Respiratory Therapeutics develops, markets and sells prescription and non-prescription pharmaceuticals for the treatment of respiratory disorders and diseases. In addition to ALLERxTM, the Adams product portfolio includes the Mucinex® and Aquatab® lines of guaifenesin-based cough and cold products.
Source: Eurekalert & othersLast reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.